![](/sites/default/files/Untitled%20design%20%2846%29.png)
12 . 09 .2023
Press release
Powered by Peptides: Galderma introduces Cetaphil Healthy Renew, a retinol alternative skincare range
![](/sites/default/files/Galderma%20logo_BlackBackground_700x525.png)
29 . 07 .2023
Press release
Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement
![H1 2023](/sites/default/files/Website_Visual_H1_2023_Results.jpg)
27 . 07 .2023
Press release
Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology
![WCD 2023: phase III Olympia 2](/sites/default/files/Nemo%20Press%20Release%20Instagram.jpg)
04 . 07 .2023
Press release
Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4
![WCD - Extensive Data](/sites/default/files/Curtain%20Raiser%20Instagram.jpg)
28 . 06 .2023
Press release
WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology
![](/sites/default/files/Galderma%20logo_BlackBackground_700x525.png)
26 . 06 .2023
Press release
Galderma raises approximately USD 1 billion for newly issued shares in a private placement round
![Restylane Eyelight](/sites/default/files/Restylane_Eyelight_News2.jpg)
05 . 06 .2023
Press release
Galderma receives FDA approval for its newest hyaluronic acid filler, Restylane® Eyelight™